Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.96 +0.47%

+$0.16 today

Market cap
$2.20B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.75M

Average 0.94M

Income Statement

Follow revenue through to earnings.

Revenue

$1.50M

FY 2025 · Annual

-78.6% YoY

Operating Income

-$287.40M

FY 2025 · Annual

Net Income

-$258.80M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.65M2.36M6.88M7.02M1.5M
Cost of Revenue53.31M82.26M118.01M163.55M0
Gross Profit(48.66M)(79.9M)(111.13M)(156.53M)1.5M
Gross Margin-1046.2%-3389.9%-1614.5%-2229.8%100.0%
Research & Development56.81M82.26M118.01M163.55M245.1M
Selling, General & Admin20.49M27.2M30.91M38.55M43.8M
Operating Expenses22.58M35.33M43.41M38.55M288.9M
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
EBITDA(66.08M)(104.2M)(139.03M)(154.69M)(255.42M)
EBITDA Margin-1420.8%-4420.9%-2020.0%-2203.5%-17028.0%
Operating Income(71.24M)(115.23M)(154.54M)(195.08M)(287.4M)
Operating Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%
Interest Income505K2.91M13.11M37.22M28.61M
Interest Expense00000
Other Income / Expenses505K2.91M13.11M37.22M28.6M
Income Before Tax(70.74M)(112.33M)(141.43M)(157.86M)(258.8M)
Pre-Tax Margin-1520.9%-4765.6%-2054.8%-2248.8%-17253.3%
Income Tax Expense(227K)0000
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.8M)
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-17253.3%
EPS (Basic)(1.64)(2.40)(2.92)(2.45)(3.90)
EPS (Diluted)(1.64)(2.40)(2.92)(2.45)(3.90)
Weighted Avg Shares42.87M46.89M48.45M64.4M66.5M
Weighted Avg Shares (Diluted)42.87M46.89M48.45M64.4M66.5M

CLDX Earnings Waterfall · TTM

NASDAQ:CLDX · Revenue to Net Income

Key Ratios

EPS$-4.31
Gross Margin-1348.3%
Net Margin-241787.8%
P/E Ratio-7.6
P/S Ratio74125.6

Analysis

$112.0K of revenue converted into -$309.1M of net income for the selected period. Gross margin is -1348.3% and net margin is -241787.8%, showing how much revenue survives after costs and taxes. EPS is $-4.31, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3ASRS-3ASR filingNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 7, 2026
8-KCurrent reportSep 22, 2026

How much revenue does CLDX generate?

Celldex Therapeutics, Inc. (CLDX) reported $1.50M of revenue in fiscal 2025.

Is CLDX profitable?

Celldex Therapeutics, Inc. (CLDX) reported -$258.80M of net income, with a net margin of -17253.3%.